NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

TNFA

TNF Pharmaceuticals Inc

Jun 30 • 04:00PM ET

0.1228

Dollar change -0.0072
Percentage change -5.54	%

Healthcare • Biotechnology • USA • NASD

Peers: PFE MRK JNJ ABBV BMY LLY GILD AMGN VRTX REGN

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-6.95	Insider Own	4.98%	Shs Outstand	14.18M	Perf Week	-11.01%
Market Cap	1.74M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	13.48M	Perf Month	-25.85%
Enterprise Value	1.16M	PEG	-	EPS next Q	-	Inst Own	1.44%	Short Float	26.70%	Perf Quarter	-65.89%
Income	-18.10M	P/S	-	EPS this Y	-	Inst Trans	-51.69%	Short Ratio	0.77	Perf Half Y	-90.33%
Sales	0.00M	P/B	0.11	EPS next Y	-	ROA	-88.26%	Short Interest	3.60M	Perf YTD	-89.32%
Book/sh	1.16	P/C	0.30	EPS next 5Y	-	ROE	-121.95%	52W High	2.16 -94.31%	Perf Year	-93.50%
Cash/sh	0.42	P/FCF	-	EPS past 3/5Y	24.22% 50.65%	ROIC	-130.74%	52W Low	0.11 7.06%	Perf 3Y	-99.82%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	15.81% 17.04%	Perf 5Y	-99.94%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	27.04%	Oper. Margin	-	ATR (14)	0.02	Perf 10Y	-100.00%
Dividend Ex-Date	-	Quick Ratio	1.37	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	32.95	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	1.37	EPS Q/Q	92.95%	SMA20	-18.10%	Beta	2.02	Target Price	32.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-28.90%	Rel Volume	0.61	Prev Close	0.13
Employees	2	LT Debt/Eq	0.00	Earnings	-	SMA200	-84.90%	Avg Volume	4.68M	Price	0.12
IPO	Jul 24, 2008	Option/Short	No / Yes	EPS/Sales Surpr.	-79.41% -14.63%	Trades		Volume	2,850,994	Change	-5.54%

Jun-24-25 09:15AM	TNF Pharmaceuticals Collaborates with DADA2 Foundation for Compassionate Use Study of Isomyosamine in Rare Pediatric Autoinflammatory Disease (Business Wire)
May-08-25 09:20AM	TNF Pharmaceuticals and Renova Health Report Positive Results in Identifying Targets for Treating TNF-Driven Inflammation in Patients Receiving GLP-1 Agonists (Business Wire)
Apr-22-25 09:15AM	TNF Pharmaceuticals and Renova Health Utilize AI to Accelerate Drug Development (Business Wire)
Apr-16-25 09:15AM	TNF Pharmaceuticals Delivers Platform Presentation of Oral TNF-Alpha Inhibitor Isomyosamine at British Geriatrics Society's Spring Meeting 2025 (Business Wire) -9.00%
Mar-18-25 09:25AM	TNF Pharmaceuticals presents isomyosamine data (TipRanks)
09:15AM	Loading…
Mar-17-25 09:15AM	TNF Pharmaceuticals Delivers Podium Presentation of Novel Oral TNF-Alpha Inhibitor at Premier International Conference on Frailty and Sarcopenia (Business Wire) +5.49%
Mar-05-25 09:00AM	TNF Pharmaceuticals to Host Investor Conference Call and Webcast Featuring Clinical Scientific Updates on Thursday, March 6, 2025 (Business Wire)
Feb-25-25 09:20AM	TNF Pharmaceuticals Initiates Phase 2b Clinical Trial of First Oral TNF-Alpha Inhibitor (Business Wire) +5.55%
Jan-29-25 09:15AM	TNF Pharmaceuticals Launches Study Series Aimed at Preserving Lean Muscle Mass During GLP-1 Weight Loss Treatment (Business Wire) -9.83%
Jan-15-25 09:15AM	TNF Pharmaceuticals Announces Positive Clinical Data Supporting Clinical Trial Expansion (Business Wire) -20.27%
Dec-19-24 09:15AM	TNF Pharmaceuticals Announces Trial to Explore Effects of Lead Candidate in Sarcopenia/Frailty Induced by GLP-1 Weight Loss Drugs (Business Wire)
Dec-09-24 09:00AM	TNF Pharmaceuticals Presents Statistically Significant Phase 2a Trial Results for Novel Sarcopenia/Frailty Treatment at Prestigious International Conference (Business Wire) +13.71%
Oct-02-24 09:10AM	TNF Pharmaceuticals Announces Strategic Equity Investment Priced at a Premium to Market (Business Wire) +18.62%
Aug-21-24 09:00AM	TNF Pharmaceuticals Prepares to Advance Lead Clinical Program Targeting Age-Related Decline (Business Wire) -11.39%
Jul-24-24 09:05AM	TNF Pharmaceuticals (Formerly MyMD Pharmaceuticals) Begins Trading Under New Nasdaq Stock Symbol TNFA Effective Before Market Open Today (Business Wire) +9.89%
09:00AM	Loading…
Jul-22-24 09:00AM	MyMD Pharmaceuticals Announces Corporate Rebranding to New Name TNF Pharmaceuticals, Inc. (Business Wire)
Jul-15-24 07:52AM	MYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
Jun-17-24 09:00AM	MyMD Pharmaceuticals Appoints Accomplished Biopharmaceutical Leader and Current Board Member, Mitchell Glass, M.D. as President and Chief Medical Officer (Business Wire)
May-21-24 09:00AM	PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease (Business Wire) -12.18%
09:00AM	MyMD Pharmaceuticals Secures Strategic Investments (Business Wire)
May-17-24 03:52PM	MYMD Stock Earnings: MyMD Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace) +7.31%
Apr-09-24 08:21AM	Why Is MyMD Pharmaceuticals (MYMD) Stock Up 35% Today? (InvestorPlace)
Mar-05-24 09:15AM	MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing (Business Wire)
Feb-13-24 11:45AM	MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing (Business Wire) -14.49%
Dec-29-23 12:45PM	MyMD Pharmaceuticals Releases Positive Clinical Trial Results For Sarcopenia Treatment Drug (ACCESSWIRE)
Dec-06-23 09:15AM	MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis (Business Wire) -5.75%
Oct-19-23 09:00AM	MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD, Reduced Acute Inflammatory Pain (Business Wire)
Oct-04-23 07:30AM	MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF- Market Disrupter, at BioFuture 2023 (Business Wire)
Aug-14-23 08:30AM	FDA Accepts MyMD Pharmaceuticals Investigational New Drug Application (IND) for Phase 2 Study of oral TNF- inhibitor MYMD-1® in Rheumatoid Arthritis (RA) (Business Wire) -7.64%
Aug-02-23 08:30AM	MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results (Business Wire)
09:00AM	Loading…
Jul-31-23 09:00AM	MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF- Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty (Business Wire) +31.82%
Apr-12-23 08:30AM	MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -8.54%
Mar-20-23 08:55AM	MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF- Inhibitor MYMD-1® in Rheumatoid Arthritis (Business Wire) -5.00%
Mar-08-23 08:30AM	MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls (Business Wire)
Mar-02-23 08:30AM	MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD is not a Controlled Substance or Listed Chemical (Business Wire) +5.62%
Feb-28-23 08:30AM	MyMD Pharmaceuticals® Announces Upcoming Presentation of Preclinical Rheumatoid Arthritis Data for Oral TNF- Inhibitor MYMD-1® at the Society of Toxicology 2023 Annual Meeting (Business Wire)
Feb-21-23 08:45AM	MyMD Announces $15 Million Offering with Existing Investors (Business Wire) -7.32%
Dec-06-22 09:40AM	ADDING MULTIMEDIA MyMD Pharmaceuticals® to Present Data on Oral TNF-a Inhibitor MYMD-1® at the British Society for Immunology (BSI) Congress 2022 (Business Wire) -9.74%
Nov-17-22 08:00AM	MyMD Pharmaceuticals® Announces Upcoming Presentation of Late-Breaking Data for MYMD-1® at the 2022 British Society for Immunology (BSI) Congress (Business Wire)
Nov-14-22 08:00AM	MyMD Pharmaceuticals Announces Publication of Phase 1 Data for oral TNF-alpha Inhibitor MYMD-1® in Peer-Reviewed Journal Drug Research (Business Wire) -5.96%
Sep-20-22 08:00AM	MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -6.25%
Aug-30-22 08:30AM	MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD Compound (Business Wire) -7.27%
Aug-03-22 09:45AM	Data Showing MyMD Pharmaceuticals MYMD-1® May Extend Life and Improve Health Published in the Journal of Gerontology: Biological Sciences (Business Wire)
Jul-29-22 09:19AM	Is MyMD Pharmaceuticals, Inc. (NASDAQ:MYMD) Popular Amongst Insiders? (Simply Wall St.) +5.79%
Jul-26-22 07:30AM	MyMD Pharmaceuticals® Advances Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -11.44%
Jul-12-22 09:30AM	MyMD Pharmaceuticals to Collaborate with Bascom Palmer Eye Institute to Study MYMD-1 in Ophthalmic Conditions (Business Wire) +17.10%
Jun-21-22 10:30AM	MyMD Pharmaceuticals Advances Phase 2 Multi-Center Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire)
Apr-05-22 09:15AM	MyMD Pharmaceuticals Accelerates Pace of New Patient Dosing in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -8.79%
Mar-24-22 09:26AM	MyMD Pharmaceuticals Announces Live Appearance on Cheddar News Network Today March 24 (Business Wire)
Feb-23-22 09:15AM	MyMD Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial of MYMD-1 as a Therapy for Delaying Aging and Extending Healthy Lifespan (Business Wire) -9.49%
Feb-20-22 08:37AM	We're Keeping An Eye On MyMD Pharmaceuticals' (NASDAQ:MYMD) Cash Burn Rate (Simply Wall St.)
Feb-08-22 09:15AM	MyMD Pharmaceuticals Announces Positive Clinical Data in Advance of Upcoming Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan (Business Wire) -5.13%
Feb-07-22 08:38PM	NorthRock Partners, LLC Buys PepsiCo Inc, iShares MSCI EAFE ETF, iShares MSCI Emerging Markets ... (GuruFocus.com)
Jan-05-22 09:15AM	MyMD Pharmaceuticals Announces Issuance of New U.S. Patent Covering MYMD-1 in a Method of Treating Sarcopenia (Business Wire) -5.26%
Dec-29-21 09:15AM	MyMD Pharmaceuticals Investment Company Oravax Medical Signs Cooperation and Purchase Agreement for Initial Pre-Purchase of 10 Million Doses of Oral COVID-19 Vaccine to be Commercialized in Southeast Asia (Business Wire)
Dec-16-21 10:50AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (PR Newswire)
Dec-01-21 10:05AM	MyMD Pharmaceuticals to Participate in Two Investor Conferences During December 2021 (Business Wire)
Nov-23-21 09:25AM	MyMD Pharmaceuticals Announces Issuance of U.S. Patent Covering Lead Drug Candidate MYMD-1 in a Method of Extending Lifespan (Business Wire)
Nov-18-21 09:15AM	MyMD Pharmaceuticals Investment Company Oravax Medical and Genomma Lab Announce Joint Venture to Develop and Commercialize Oral COVID-19 Vaccine in Mexico and Drive Business Development in Latin America (Business Wire) -9.76%
Nov-16-21 09:25AM	MyMD Pharmaceuticals Receives FDA IND Clearance to Begin Phase 2 Trial of MYMD-1 for Extending Healthy Lifespan (Business Wire) -11.75%
Nov-15-21 09:45AM	SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating MyMD Pharmaceuticals, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors (ACCESSWIRE)
Oct-26-21 10:30AM	MyMD Pharmaceuticals President Chris Chapman, M.D. Named Medical Honoree of the Year by the Arthritis Foundation (Business Wire)
Oct-19-21 10:30AM	MyMD Pharmaceuticals to Discuss its Novel Therapies for Aging and Related Diseases at the Dawson James Securities 6th Annual Small Cap Growth Conference on October 21 (Business Wire) +6.56%
Oct-05-21 10:00AM	MyMD Pharmaceuticals to Detail its Two Upcoming Phase 2 Trials at the Benzinga Rising Stars: Catalytic Small Cap Growth Conference on October 7 (Business Wire)
Sep-22-21 11:00AM	MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD (Business Wire)
Sep-13-21 10:00AM	MyMD Pharmaceuticals Announces Fourth Quarter 2021 Initiation of Phase 2 Clinical Trial of MYMD-1 for Extending Healthy Lifespan (Business Wire) -9.30%
Sep-09-21 10:15AM	MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15 (Business Wire)
Aug-24-21 10:17AM	MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Use of Lead Candidate MYMD-1 for Treating Fibrosis and Asthma (Business Wire)
Aug-23-21 08:47AM	We Think MyMD Pharmaceuticals (NASDAQ:MYMD) Can Afford To Drive Business Growth (Simply Wall St.) +5.02%
Aug-10-21 02:30PM	MyMD Pharmaceuticals Announces Issuance of U.S. Patent for Synthetic Cannabinoid Compounds for Treating Neuroinflammatory and Neurodegenerative Diseases (Business Wire) +13.75%
10:30AM	MyMD Pharmaceuticals Subsidiary Oravax Medical Preparing to Commence Clinical Trials for Oral COVID-19 Vaccine (Business Wire)
Aug-05-21 10:30AM	MyMD Pharmaceuticals Lead Compound MYMD-1 Shown to Suppress a Major Cause of Death in COVID-19 in Human Cell Study (Business Wire) +8.46%
Jul-27-21 09:15AM	MyMD Pharmaceuticals Lead Compound MYMD-1 Shows Commonality in Comparative Study with FDA-Approved Anti-Inflammatory and Anti-Autoimmune Drugs Used for Arthritis, Colitis and Dermatitis (Business Wire)
Jul-07-21 09:00AM	MyMD Pharmaceuticals Announces New Data from Comparative Study on Lead Compound MYMD-1 (Business Wire) -12.50%
Jun-07-21 10:02AM	MyMD Pharmaceuticals Set to Join Russell Microcap® Index (Business Wire)
May-17-21 09:00AM	MyMD Pharmaceuticals Appoints David Rini, Professor at the Johns Hopkins School of Medicine, to Scientific Advisory Board (Business Wire)
May-12-21 09:00AM	MyMD Pharmaceuticals Schedules Business Update Conference Call (Business Wire)
May-10-21 09:00AM	MyMD Pharmaceuticals: Invitation to the Benzinga Global Small Cap Conference (Newsfile)
Apr-28-21 10:13AM	Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit (Business Wire) +10.92%
Apr-22-21 09:20AM	MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds (Business Wire)

TNF Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of drug products to extend healthy lifespan. It focuses on developing two novel therapeutic platforms, MyMD-1 and SUPERA-CBD, which aim to treat the causes of disease rather than just addressing the symptoms. MyMD-1 is a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cytokines. SUPERA-CBD is a synthetic derivative of cannabidiol being developed to treat conditions such as epilepsy, chronic pain, depression, as well as neuroinflammatory and neurodegenerative diseases. The company was founded in 1989 and is headquartered in New York, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TNFA

TNF Pharmaceuticals Inc

Upgrade your FINVIZ experience